Supportive management of patients with brain tumors

Expert Review of Neurotherapeutics

Volumn 7, Issue 10, 2007, Pages 1327-1336

  Daly, Farrah N ^a   Schiff, David ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Brain tumor; Cerebral edema; Palliative care; Seizure; Venous thromboembolism

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; COTRIMOXAZOLE; DALTEPARIN; DEXAMETHASONE; DONEPEZIL; ENOXAPARIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; METHYLPHENIDATE; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOTIC DIURETIC AGENT; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; STEROID; TEMOZOLOMIDE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VITAMIN D; WARFARIN;

ADRENAL INSUFFICIENCY; AGITATION; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN DISEASE; BRAIN EDEMA; BRAIN TUMOR; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; INFECTION SENSITIVITY; INSOMNIA; LOW DRUG DOSE; MANIA; MYOPATHY; NAUSEA AND VOMITING; NEUTROPENIA; OSTEOPOROSIS; PAIN; REVIEW; SEIZURE; SIDE EFFECT; SKIN FRAGILITY; SLEEP DISORDER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE MANAGEMENT; HUMANS; PALLIATIVE CARE; SEIZURES;

EID: 35548963897     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.10.1327     Document Type: Review

References (105)

1. Kaal Evert CA, Vecht CJ. The management of brain edema in brain tumors. Curr. Opin. Oncol. 16, 593-600 (2004). •• Concise review of physiology and treatment of brain edema
2. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat. 200, 639-646 (2002).
3. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience 129, 1011-1020 (2004).
4. Bedford RF, Morris L, Jane JA. Intracranial hypertension during surgery for supratentorial tumor: correlation with preoperative computed tomography scans. Anesth. Analg. 61, 430-433 (1982).
5. Fadul C, Wood J, Thaler H, Galicich J, Patterson RH, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 38, 1374-1379 (1988).
6. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42(5), 1083-1099 (1998).
7. Gomes J, Stevens R, Lewin III J, Mirski M, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit. Care Med. 33(6) 1214-1224 (2005).
8. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. Am. J. Neuroradiol. 27, 402-408 (2006).
9. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J. Neurol. Neurosurg. Psychiatr. 75, 1632-1635 (2004).
10. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas D, Doherty, L. Medical management of patients with brain tumors. J. Neurooncol. 80(3), 313-332 (2006). •• Recent and complete review of symptomatic management of brain tumors.
11. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteroporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 44(7), 1496-1503 (2001).
12. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: recommendations of the US Public Health Service and the Infectious Diseases Society of America. Ann. Intern. Med. 137, 435-478 (2002).
13. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int. J. Rad. Onc. Biol. Phys. 62(5), 1423-1426 (2005).
14. DaSilva AN, Schiff D. Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. Surg. Neurol. 67, 508-510 (2007).
15. Sur P, Sribnick E, Patel S, Ray S, Banik N. Dexamethasone decreases temozolomide-induced apoptosis in human glioblastoma T98G cells. Glia 50, 160-167 (2005)
16. Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med. Wkly 132(29-30), 425-426 (2002).
17. Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann. Pharmachother. 30(5), 520-526 (1996).
18. Carr L, Mechtler L, Recht L. The effect of corticorelin acetate on peritumoral brain edema: An interim report of an open-label study as part of a Phase III program. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18S), 9095 (2007).
19. Batchelor T, Sorenson AG, di Tomaso E. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95, (2007).
20. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 1258-1260 (2006).
21. Gonzalez J, Kumar A, Conrad C, Levin V. Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 323-326 (2007).
22. Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment inpatients with cancer and venous thrombosis. Blood 100(10), 3484-3488 (2002).
23. Heit J. Cancer and venous thromboembolism: the scope of the problem. Cancer Control 12, S1 (2005).
24. Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data. Medicine (Baltimore) 78(5), 285-291 (1999).
25. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr. Opin. Pulm. Med. 7, 326-331 (2001).
26. Marras LC, Geerts W, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89(3), 640-646 (2000).
27. Gerber D, Grossman S, Streiff M. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J. Clin. Oncol. 24, 1310-1318 (2006).
28. Semrad TJ, O'Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J. Neurosurg. 106(4), 601-608 (2007).
29. Roderick P, Ferris G, Wilson K. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran, and regional anesthesia as thromboprophylaxis. Health Technol. Assess. 9(49), 1-78 (2005).
30. Cerrato D, Ariano C, Fiacchino F. Deep venous thrombosis and low dose heparin prophylaxis in neurosurgical patients. J. Neurosurg. 49(3), 378-381 (1978).
31. Agnelli G, Piovella F, Buoncristiani P et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N. Engl. J. Med. 339, 80-85 (1998).
32. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch. Intern. Med. 160(15), 2327-2332 (2000).
33. Rogers FB, Cipolle M, Velmahos G, Rozycki G, Luchette F. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines workgroup. J. Trauma 53(1), 142-164 (2002).
34. Geerts W. Prevention of venous thromboembolism in high risk patients. Hematology Am. Soc. Hematol. Educ. Program 462-466 (2006).
35. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 126(Suppl. 3), S338-S400 (2004).
36. Goldhaber S, Dunn K, Gerhard-Herman M, Park J, Black P. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122, 1933-1937 (2002).
37. Lee AY. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Curr. Opin. Pulm. Med. 9, 351-355 (2003).
38. Macdonald R, Amidei C, Baron J et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg. Neurol. 59, 363-374 (2003).
39. Sherman DG, Albers GW, Bladin C et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischemic stroke (PREVAIL Study): an open-label randomized comparison. Lancet 369, 1347-1355 (2007).
40. Klerk C, Smorenburg S, Otten H et al. The effect of low molecular weight heparin on survival inpatients with advanced malignancy. J. Clin. Oncol. 23, 2130-2135 (2005).
41. Balzarotti M, Fontana F, Marras C et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion inprimary cell cultures of high-grade gliomas. Oncol. Res. 16(5), 245-250 (2006).
42. Lee AY, Rickles FR, Julian JA. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23, 2123-2129 (2005).
43. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost. 5(4), 729-737 (2007).
44. North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB. Phenytoin and postoperative epilepsy. A double-blind study. J. Neurosurg. 58(5), 672-677 (1983).
45. Lee AY, Levine MN, Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146-153 (2003).
46. Monreal M, Zacharski L, Jimenez JA, Roncaless J, Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J. Thromb. Haemost. 2, 1311-1315 (2004).
47. Meyer G, Marjanovic Z, Valche J et al. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch. Intern. Med. 162, 1729-1735 (2002).
48. Perry JR, Rogers L, Laperriere N et al. PRODIGE: a Phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin in patients with newly diagnosed malignant glioma. J. Clin. Oncol. 25(Suppl. 18), 2011 (2007).
49. Hildebrand J, Lecaille C, Perennes J, Delattre J. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65, 212-215 (2005).
50. Van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 6, 423-430 (2007). •• Clear review of issues related to epilepsy management in patients with brain tumors.
51. Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4), 985-991 (1996).
52. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis inpatients withnewly diagnosed brain tumors: Report of the Quality Standards Sucommittee of the American Academy of Neurology. Neurology 54(10), 1886-1893 (2000).
53. Sander J. The use of antiepileptic drugs - principles and practice. Epilepsia 45(Suppl. 6), 28-34 (2004).
54. Sirven JI, Wingerchuk DM, DrazkowskiJF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin. Proc. 79(12), 1489-1494 (2004).
55. Brouwers MC, Chambers A, Perry J. Can surveying practitioners about their practices help identify priority clinical practice guideline topics? BMC Health Serv. Res. 3, 23 (2003).
56. Siomin V, Angelov L, Li L, Vogelbaum M. Results of a survey of neurosurgical practice patterns regarding prophylactic use of anti-epilepsy drugs in patients with brain tumors. J. Neurooncol. 74(2), 211-215 (2005).
57. Taillibert S, Delattre J. Palliative care in patients with brain metastases. Curr. Opin. Oncol. 17, 588-592 (2005).
58. Manaka S, Ishijima B, Mayanagi Y. Postoperative seizures: epidemiology, pathology, and prophylaxis. Neurol. Med. Chir. (Tokyo) 43, 589-600 (2003).
59. North JB, Penhall RK, Hanieh A, Hann CS, Challen RG, Frewin DB. Posoperative epilepsy: a double-blind trial of phenytoin after craniotomy. Lancet 1(8165), 384-386 (1980).
60. Mahaley MS, Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg. Neurol. 16(6), 399-401 (1981).
61. Shaw MDM, Foy PM. Epilepsy after craniotomy and the place of prophylactic anticonvulsant drugs: discussion paper. J. R. Soc. Med. 84, 221-223 (1991).
62. Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 5(4), 291-298 (1996).
63. Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenité DG et al. Comparative double blind clinical trial of pheytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J. Neurol. Neurosurg. Psychiatr. 67(4), 474-480 (1999).
64. DeSantis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43(2), 175-182, (2002).
65. Cavaliere R, Farace E, Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch. Neurol. 63(12), 1746-1749 (2006).
66. DeAngelis LM. Brain tumors. N. Engl. J. Med. 344(2), 114-123 (2001).
67. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 41(2), 107-139 (2000).
68. Taylor LP, Posner JB. Phenobarbital rheumatism in patient with brain tumor. Ann. Neurol. 25(1), 92-94 (1989).
69. Micali G, Linthicum K, Han N, West DP. Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies. Pharmacotherapy 19(2) 223-227 (1999).
70. Murry D, Cherrick I, Salama V et al. Influence of phenytoinon the disposition of irinotecan: a case report. Am. J. Pediatr. Hematol. Oncol. 24(2), 130-133 (2002).
71. Van den Bent MJ. The role of chemotherapy in brain metastases. Eur. J. Cancer 39, 2114-2120 (2003).
72. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J. Neurooncol. 72(3), 255-260 (2005).
73. Wen P, Marks P. Medical management of patients with brain tumors. Curr. Opin. Oncol. 14, 299-307 (2002).
74. Kikuchi K, McCormick CI, Neuwelt EA. Immunosuppression by phenytoin: implication for altered immune competence in brain-tumor patients. J. Neurosurg. 61(6), 1085-1090 (1984).
75. Suwanwela N, Phanthumchinda K, Kaoropthum S. Headache in brain tumor: a cross-sectional study. Headache 34(7), 435-438 (1994).
76. Forsyth PA, Posner JB. Headache in patients with brain tumors: a study of 111 patients. Neurology 43(9), 1678-1683 (1993).
77. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications- review and recommendations based on risk assessment. Aliment Pharmacol. Ther. 19(10), 1051-1061 (2004).
78. Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of anti-inflammatory drugs. Ann. Intern. Med. 114, 735-740 (1991).
79. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoetins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J. Natl Cancer Inst. 98, 708-714 (2006).
80. Bohlius J, Langensiepen S, Schwarzer G et al. Erythropoetin for patients with malignant disease. Cochrane Database Syst. Rev. 3, CD003407 (2004).
81. Ross S, Allen E, Henry D, Seaman C, Sercus B, Goodnough L. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther. 28(6), 801-831 (2006).
82. Khuri F. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N. Engl. J. Med. 356(24), 2445-2448 (2007).
83. Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 19(9), 725-727 (2005).
84. Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression, and quality of life of mixed-site cancer patients and their partners. Psychooncology 15(3), 259-267 (2006).
85. Hanna A, Sledge G, Mayer ML et al. A Phase II study of methylphenidae for the treatment of fatigue. Support Care Cancer 14(3), 210-215 (2006).
86. Bruera E, Valero V, Driver L et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J. Clin. Oncol. 24, 2073-2078 (2006).
87. Fox S, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J. Nurs. Scholarsh. 39(1), 61-67 (2007)
88. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J. Neurooncol. 57(1), 41-49 (2002).
89. Schmidinger M, Linzmayer L, Becherer A et al. Psychometric and quality of life assessment in long-term glioblastoma survivors. J. Neurooncol. 63, 55-61 (2003).
90. Gottwald B, Wilde B, Mihaljlovic Z, Mehdorn HM. Evidence for distinct cognitive deficits after focal cerebellar lesions. J. Neurol. Neurosurg. Psychiatr. 75, 1524-1531 (2004).
91. Sherwood PR, Given BA, Given CW et al. Predictors of distress in caregivers of persons with a primary malignant brain tumor. Res. Nurs. Health 29(2), 105-120 (2006).
92. Correa DD. Cognitive functions in brain tumor patients. Hematol. Oncol. Clin. North Am. 20(6), 1363-1376 (2006).
93. Brown PD, Jensen AW, Felten SJ et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J. Clin. Oncol. 24(34), 5427-5433 (2006).
94. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J. Clin. Oncol. 16(7), 2522-2527 (1998).
95. Mulhern R, Khan R, Kaplan S. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J. Clin. Oncol. 22, 4795-4803 (2004)
96. Conklin H, Khan RB, Reddick WE et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J. Pediatr. Psychol. (2007) (Epub ahead of print).
97. Shaw E, Rosdhal R, D'Agostino RB et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J. Clin. Oncol. 24, 1415-1420 (2006).
98. Butler JM, Rapp SR, Shaw EG. Managing the cognitive effects of brain tumor radiation therapy. Curr. Treat. Options Oncol. 7(6), 517-523 (2006).
99. Cohen M, Johnson J, Pazdur R. Food and Drug Administration Drug Approval Summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin. Cancer Res. 11(19), 6767-6771 (2005).
100. Taphoorn M, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomized conrolled trial. Lancet Oncol. 6, 937-944 (2005).
101. Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith T. Improving palliative and supportive care in cancer patients. Oncology 19(10), 1365-1376; discussion 1377-8, 1381-2, 1384 passim (2005).
102. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 58(Suppl. 5), S9-S19 (2002).
103. Brandes AA, Compostella A, Blatt V, Tosoni A. Glioblastoma in the elderly: current and future trends. Crit. Rev. Oncol. Hematol. 60, 256-266 (2006).
104. Noble SIR, Nelson A, Turner I, Finlay G. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. Br. Med. J. 332, 577-580 (2006).
105. National Comprehensive Cancer Network. Cancer-Related Fatigue. V3. (Accessed 3rd August 2007) http://www.nccn.org/professionals/physician_gls/PDF/ fatigue.pdf